With a slashed valuation the newly listed biotech heads for phase 3.
ApexOnco Front Page
Recent articles
An actinium-based backup and Werner helicase inhibitor are notable absences.
A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
Efficacy looks better with daraxonrasib plus chemo versus monotherapy, but toxicity looms.
Pivotal data set the stage for slightly delayed US accelerated approval filing.
But first it will need to identify the optimal dose in first-line small-cell lung cancer.
Inlexzo gets the nod in BCG-unresponsive non-muscle invasive bladder cancer, but the group has bigger plans.
So far the data, with a Car-T Legend licensed to Novartis, lag antibody approaches.
